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ABSTRACT
Objective: This study was undertaken to determine the link between the presence of “atypical” infections in patients with acute obstructive and 
recurrent obstructive bronchitis (AOB/ROB) and bronchial asthma (BA) development based on the concept of risk.
Methods: The materials for the study were the data records of patients hospitalized with AOB or ROB and whose analysis was performed to identify 
antibodies to “atypical” microflora (796 patients). The study period was 4 years from 2008 to 2011. In the analyzed period, immunosorbent assay for 
the detection of antibodies to “atypical” microflora (Chlamydophila pneumoniae, Mycoplasma pneumoniae, Mycoplasma hominis) was performed. The 
concept of risk identification was based on the determination of the absolute risk, attributable risk (AtR), relative risk, population attributable risk, as 
well as on the definition of the standard errors for each type of risk and the confidence interval.
Results and Conclusion: Methodical aspects of determining the relationship between the presence of “atypical” infections in patients with AOB 
or ROB and BA development were based on the concept of risk. The analysis showed a direct link between the increase of cases of BA formation 
against the backdrop of “atypical” infections. Therefore, the performed analysis of atypical pathogens influences on BA occurrence in patients with 
AOB/ROB which indicates direct dependence increase of BA incidence on atypical infection. In experimental group, Frequency of event is 14.84% in 
experimental group. Frequency of event is 1.67% in control group. The risk factor increases probability of event by 13.17%, the risk factor increases 
probability of event by 13.17%. Presence of atypical infection leads to increase of BA incidence by 8.9 times. Number needed to harm (NNH) is 7.59, 
i.e., in the presence of atypical infection in patients with AOB/ROB, each eighth exposed person develops BA in addition to background level of BA 
incidence.
Keywords: Acute obstructive bronchitis, Recurrent obstructive bronchitis, Bronchial asthma, The concept of risk, Risk factor, The absolute risk, 
Relative risk, Attributable risk, Population attributable risk, Number needed to harm.
INTRODUCTION
Acute obstructive bronchitis (AOB) is a common disease, which affects 
10-15% of child population. AOB incidence is increasing globally. More 
than 50% of infants may develop recurrent obstructive bronchitis 
(ROB) in association with acute viral respiratory infection (AVRI) [1]. 
If bronchitis with bronchial obstructive syndrome (BOS) occurs at 
least 2-3 times a year, ROB develops. Bronchial asthma (BA) is also the 
common cause of recurrent incidence of BOS.
Nowadays, continuous increasing incidence and the severity of BA 
are noted. BA is often evolved in children at an early age, hence it is a 
considerable problem [2]. Microbe-virus associations were proved, in 
which one of the infectious agents is intracellular pathogen, for example, 
Chlamydophila pneumoniae, Mycoplasma pneumoniae, Legionella spp. 
etc., play an important role in bronchial obstructive disease, may cause 
exacerbation and severe course of disease. In recent years, numerous 
researches of atypical role of respiratory pathogens in recurrent BOS 
are performed [3,4].
In epidemiological and clinical researches, often it is necessary to 
evaluate the power of interaction between impact and outcome 
(disease, complications, death, etc.) when parameters are paired, 
i.e., they are alternative outcomes for research subjects. In general, 
risk concept considers ratio between participants, who is exposed and 
not exposed of any factor. Hence, risk concept evaluated the effect of 
smoking on the occurrence of chronic obstructive pulmonary disease 
exacerbations [5].
The purpose of this research is to reveal the interaction between the 
presence of atypical infections in patients with AOB, ROB, and BA, 
according to risk conception.
METHODS
Study site
The study was conducted in a hospital in Nizhny Novgorod.
Study population
The study included stroke patients who underwent treatment.
Study design
The design of the study was of retrospective type.
Period of the study
The study was performed for 4 years (2008-2011).
Inclusion criteria
In the research, we applied medical records of patients, who were 
hospitalized with AOB/ROB and in whom antibody test for “atypical” 
microflora (796 patients) was performed.
Over a period of study, enzyme immunoassay for atypical microflora 
(C. pneumonia, Mycoplasma pneumoniae, and Mycoplasma hominis) 
antibodies was performed.
IgA antibodies were detected in 256 (32.2%) examined patients.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Methodology of data processing
Detection risk concept was built on absolute risk (AR) detection in 
exposed group (ARe) and in unexposed group (ARu) (i.e., in patients 
with concurrent atypical infection and without concurrent atypical 
infection, respectively), on attributable risk (AtR), relative risk (RR), 
population AtR (PAR), and also on the detection of standard error for 
all risk types and confidence interval (CI).
RESULTS
Analysis of risk for occurrence of BA in patients with AOB and ROB 
begins with the construction of table of conjugate distributions 
(Table 1). Rows and columns of this table are arranged in certain 
order. Therefore, parameters that were calculated from this table in the 
course of research make a sense and may be interpreted correctly. The 
first row assigns for exposed group, which consists of children having 
studied risk factor, i.e., patients with BOS and concurrent atypical 
infection. The second row assigns for values, characterizing of BA 
risk in patients with BOS, but without atypical infection. The studied 
risk factor was absent in this group. In summary, the first group is 
interesting for investigators, i.e., patients in this group were exposed to 
risk factor. Values in the second row have been received from unexposed 
group, i.e., from patients without concurrent atypical infection. In the 
first column, it is recorded how many times the investigated event 
(risk of BA occurrence) was registered in exposed group (patients 
with concurrent atypical infection) and in unexposed group (without 
concurrent atypical infection). In the second column, it is recorded how 
many times investigated event was absent.
In the beginning, hypothesis is formed that presence of atypical infection 
in patients with BOS may lead to BA. First of all, AR is calculated, i.e., 
proportion of ill in the whole group (in exposed and unexposed groups 
separately). In our case, it means computation of BA risk in group of 
patients with/without concurrent atypical infection. By Formula (1), 
we calculate the frequency of BA occurrence in exposed group (with 





In other words, 0.1484 or 14.84% of patients in the exposed group 
have a risk of BA. By Formula (2), we calculate the frequency of BA 
occurrence in unexposed group (without atypical infection), i.e., 1.67%:
cARu=
B  (2)
As a result, we have the so-called point estimates of BA occurrence 
frequency in experimental and control groups. Point estimates may 
have statistical error, hence in the next sample, we may receive 
different values because we calculate these frequencies not on the 
base of whole population but on the base of representative parts, 
which just approximately reflects the features of population. Therefore, 
it is necessary to calculate the standard error of received AR, i.e., 
statistical error of each frequency, which indicates the accuracy of 
estimate. Standard error for AR in the exposed group was calculated by 





Table 1: Table of conjugate distributions
Atypical infection Risk of BA Total
Yes No
Present 38 (а) 218 (b) 256 (A)
Not present 9 (с) 531 (d) 540 (B)
Total 47 (C) 749 (D) 796 (Q)
BA: Bronchial asthma
Where n - volume of exposed or unexposed group, i.e., A or B.
Standard error for AR in the unexposed group was calculated similarly 
at 0.005.
The received frequencies may change in case of calculation in other 
samples. Therefore we need to define how these changes will be 
significant, and minimal intervals of values involve actual precise values 
of required frequencies. We define minimal interval, which consists from 
actual value of required frequency with probability of 95%. In statistics, 
such interval is named 95% (95% CI). From a practical point of view, 
95% CI means that 95% of all potential samples give frequencies that 
are included in received intervals, but 5% will be out of these intervals. 
In research, 95% CI or 99% CI is used mostly.
We calculate 95% CI for AR of exposed group at 0.1484+0.0431 or 
14.84 ± 4.31% by Formula (4):
CI =AR±t×SAR  (4)
Where t - critical value for statistical significance. For 95% CI, t=1.96,
S - Standard error of AR.
In other words, minimal value of 95% CI is 10.53%, maximal value is 
19.15%, mean ARe is 14.84%, and standard error is 2.20%.
To summarize, the presence of concurrent atypical infections in the 
studied group led to BA occurrence in 14.84±2.20%, 95% of all possible 
values of incidence are included in interval at 10.53-19.15%.
Analogically on Formula (4), 95% CI for AR in unexposed group was 
calculated: 0.0167±0.0098 or 1.67±0.98%.
In other words, without concurrent atypical infection, the risk of BA 
occurrence in control group is 1.67±0.98%. 95% of all possible values 
of incidence are included in interval 0.69-2.65%.
Thus, absolute values of morbidity in exposed and unexposed groups 
were received. Therefore, under the impact, BA occurrence increases. 
But how significant is the role of risk factor in this increasing? AtR is 
estimated, which characterizes risk parts that are associated with this 





In other words, in experimental group, Frequency of event is 14.84% in 
experimental group. Frequency of event is 1.67% in control group. The 
risk factor increases probability of event by 13.17%.
For calculation of standard error of received distinction, it is necessary 





Then, we determined standard error of AtR by Formula (7). It was 
0.0183 or 1.83%.
AtR
1 1S = F (1 F) .
A B
 × − × +    (7)
Then, we calculated 95% CI for AtR: 0.1317±0.0359 or 13.17%±3.59%.
To summarize, the presence of concurrent atypical infections in 
patients with AOB of ROB leads to increased risk of BA occurrence by 
13.17±1.83%. 95% of possible (true) values of difference of morbidity 
were included in interval 9.58 - 16.76%. Therefore, possible (true) 
values, which are included in 95% CI, may indicate about ARe>AR, i.e., 
atypical infection increases of BA risk.
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If ARe=ARu, impact of risk factor does not change the probability of 
event. If ARe<ARu, impact of risk factor does not change the possibility 
of event.
Risk estimation methodology is based on statistical parameters (mean, 
mean error, CI), which are based on probability theory. Therefore, when 
we calculate any risk, we should talk not about absolute (precision) 
dependence of outcome from factor but about the probability degree 
of this dependency. In turn, dependence of the outcome from the factor 
may be significant. In this case, statistical reliable probability of such 
dependence may be revealed in small samples. If dependence of the 
outcome from the factor is insignificant, for detection of statistical 
reliable probability, big samples are needed, sometimes whole 
population (e.g., population of certain region).
Analogically considering the features of CI AtR, it is necessary to analyze 
CI for all calculating risks. For example, in ARe and ARn, calculated 
earlier CI (10.53 and 19.15%, 0.69 and 2.65%, respectively) did not 
involve 0 or negative values. Consequently, these CIs may be considered 
statistically significant.
Through AtR, it has been demonstrated that presence of atypical 
infection leads to increase of BA risk on an average of 13.17%.
Through calculation of RR (risk ratio or relative risk), we may 
demonstrate the power of dependence between impacting risk factor 
and outcome, i.e., how many times BA morbidity increases in the 
presence of atypical infection in patients with AOB and ROB. If BA 
occurred more often in exposed group, ratio of ARe/ARn is >1. If BA 
morbidity is equal in both groups, ARe/ARn ratio equals to 1. Thus, 
according to hypothesis, from mathematical point of view, it is necessary 
to prove that ratio of BA occurrence in both groups is more than 1.
RR was calculated by Formula (8) and equals to 8.9.
aARe ARR= cARu B
=  (8)
In other words, presence of atypical infection leads to increase of 
BA occurrence by 8.9 times. However, when we are talking about 
calculation, made on sample, it is necessary to show a statistical 
significance of received result. For this purpose, standard error of RR 
was calculated, it equals to 0.3619.
H
OP
1 AP 1 APS =
a c
− ∋ −+  (9)
By Formula (10), we calculated 95% CI of RR, received value of 
8.9±4.71%.
RR
AReCI RR Exp ln ×t×S
ARu
 = ±     (10)
The received values of RR are 8.9±0.3619 with 95% CI of 4.19-13.61 






Therefore, 95% CI values indicate the importance of our hypothesis 
about atypical microflora influence on BA occurrence.
PAR is absolute difference of values (or risk) in whole population and 
in the unexposed group. PAR similar to AtR. But population component 
describes the risk component in the whole population. PAR depends 
upon how widespread risk factors in this population. PAR varies 
depending on risk factor distribution in population.







In other words, the presence of atypical infection leads to morbidity 
increase in the whole population by 4.2%.
For calculation of standard error of received difference, it is necessary 
to compute the combined estimate of the proportion. Standard error of 
AR in the exposed group was calculated by Formula (6) - 0.059.
By Formula (12), we can calculate mean error, it received 0.0134 or 
1.34%.
( )PAR 1 1S 1 F +Q BF
 
= × − ×     (12)
By Formula (13), we can calculate 95% CI PAR. It is 0.042±0.026 or 
4.20±2.60%.
PARCI PAR t×S= ±  (13)
Thus, the presence of atypical infection increases BA morbidity in 
population by 4.20±1.34%, 95% CI equals from 1.6% to 6.8% (Fig. 2).
There is another parameter, which is a derivative from AtR, number 
needed to harm (NNH) or number needed to treat (NNT). If exposure 
factor presumably caused negative changes in health status, we are 
speaking about NNH. If exposure factor improves health status (e.g., new 
treatment method decreases the number of recurrences, prophylactic 
measures decrease of incidence), we mean NNT. Both parameters are 





Fig. 1: Corridor fluctuation relative risk values with 95% 
confidence interval of bronchial asthma by persistent infection 
with atypical pathogens
Fig. 2: Corridor fluctuation population attributable risk values 
with 95% confidence interval of bronchial asthma by persistent 
infection with atypical pathogens
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NNH for atypical infection in the above-mentioned example is 7.59.
In other words, in the presence of atypical infection in patients with 
AOB/ROB, each eighth exposed person develops BA in addition to the 
background level of BA incidence.
DISCUSSION
The results on the effect of atypical microorganisms on the formation 
of BA are consistent with previous results. Etiology of AOB and its 
recurrences can be different: It can be viral, bacterial, fungal, parasitical, 
mixed, or allergic. From a practical perspective, in pediatrics, there 
are viral and bacterial bronchitis. In some cases, bronchitis may be 
caused by atypical microflora (Mycoplasma, Chlamydophila, Legionella, 
Pneumocystis), sometimes by mycology. Influenza and Para influenza 
viruses, adenoviruses, respiratory syncytial virus, coronavirus, 
rhinovirus, Coxsackie, and ECHO viruses are the most frequently 
occurring among viral causative agents. Pneumococcus (Streptococcus 
pneumoniae), Haemophilus influenzae, and Moraxella (Moraxella 
catarrhalis) are leading among bacterial causative agents at the present 
time [6].
Mycoplasmal and chlamydial etiologies of bronchitis occur most 
frequently in children at their first year of life and after 10 years, it can 
amount to 25-40% of cases [7].
It is important in each case to determine the cause of recurring and make 
a true diagnosis. In many cases, BA is a cause. For a long time disguising 
under the mask of acute respiratory infection with AOB, BA remains 
undiagnosed timely and, therefore, patients do not receive treatment. 
Only after years, it is founded in part of children that the so-called 
obstructive bronchitis turns into typical BA. According to the results 
of long-term follow-up (Yu and Mizernitsky, 2005), 4-8 years after 
hospitalization associated with expressed BO with acute respiratory 
infection, more than half of the examined children suffered from typical 
BA that had not been diagnosed in the early age. Diagnostics and timely 
beginning of corresponding therapy in a large part determine disease 
prediction.
According to multiple data from literature, the most important aspect 
for patients with BO of relapsing course (including those with BA) 
concerns studying the role of microbial and viral associations when 
one of the agents is the intracellular causative agent (C. pneumonia, 
Mycoplasma pneumoniae, Legionella spp., and others) [8,9]. It has been 
established that intracellular causative agents can both cause debut of 
bronchial obstruction disease and trigger its aggravation and perform 
severe variants of treatment [10,11].
It is known that Chlamydophila and Mycoplasma can actively affect 
immune response of a child contributing, from one point, to secondary 
introduction of infection and, from the other, to increase bronchial 
hyperactivity and development of bronchospasm. Thus, frequency of 
BO development accompanied by respiratory infection of chlamydial 
etiology amounts to 18-58% [12]. Studies of antibacterial therapy of 
AOB, which conducted by us previously, show high efficiency macrolide 
in comparison with beta-lactams. This fact confirms the high frequency 
of proliferation of atypical microorganisms in AOB in children [13].
CONCLUSION
Therefore, the performed analysis of atypical pathogens influences 
on BA occurrence in patients with AOB/ROB which indicates direct 
dependence increase of BA incidence on atypical infection. In 
experimental group, Frequency of event is 14.84% in experimental 
group. Frequency of event is 1.67% in control group. The risk factor 
increases probability of event by 13.17%. The presence of atypical 
infection leads to increase of BA incidence by 8.9 times. NNH is 7.59, 
i.e., in the presence of atypical infection in patients with AOB/ROB, each 
eighth exposed person develops BA in addition to background level of 
BA incidence.
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